Department of Gastroenterology, Wushan County People's Hospital of Chongqing, No.168, Guangdongxi Road, Wushan County, Chongqing, 404700, People's Republic of China.
Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, NO.76, Linjiang Road, Chongqing, 400010, People's Republic of China.
Dig Dis Sci. 2024 May;69(5):1852-1862. doi: 10.1007/s10620-024-08382-0. Epub 2024 Mar 21.
Early rebleeding is a significant complication of endoscopic treatment for esophagogastric variceal hemorrhage (EGVH). However, a reliable predictive model is currently lacking.
To identify risk factors for rebleeding within 6 weeks and establish a nomogram for predicting early rebleeding after endoscopic treatment of EVGH.
Demographic information, comorbidities, preoperative evaluation, endoscopic features, and laboratory tests were collected from 119 patients who were first endoscopic treatment for EGVH. Independent risk factors for early rebleeding were determined through least absolute shrinkage and selection operator logistic regression. The discrimination, calibration, and clinical utility of the nomogram were assessed and compared with the model for end-stage liver disease (MELD), Child-Pugh, and albumin-bilirubin (ALBI) scores using receiver-operating characteristic (ROC) curves, calibration plots, and decision curve analyses (DCA).
Early rebleeding occurred in 39 patients (32.8%) within 6 weeks after endoscopic treatment. Independent early rebleeding factors included gastric variceal hemorrhage (GVH), concomitant hepatocellular carcinoma (HCC), international normalized ratio (INR), and creatinine. The nomogram demonstrated exceptional calibration and discrimination capability. The area under the curve for the nomogram was 0.758 (95% CI 0.668-0.848), and it was validated at 0.71 through cross-validation and bootstrapping validation. The DCA and ROC curves demonstrated that the nomogram outperformed the MELD, Child-Pugh, and ALBI scores.
Compared with existing prediction scores, the nomogram demonstrated superior discrimination, calibration, and clinical applicability for predicting rebleeding in patients with EGVH after endoscopic treatment. Therefore, it may assist clinicians in the early implementation of aggressive treatment and follow-up.
内镜治疗食管胃静脉曲张出血(EGVH)后早期再出血是一个重要的并发症。然而,目前还缺乏可靠的预测模型。
确定内镜治疗 EGVH 后 6 周内再出血的危险因素,并建立预测早期再出血的列线图。
收集了 119 例首次接受内镜治疗 EGVH 的患者的人口统计学信息、合并症、术前评估、内镜特征和实验室检查。通过最小绝对收缩和选择算子逻辑回归确定早期再出血的独立危险因素。使用受试者工作特征(ROC)曲线、校准图和决策曲线分析(DCA)评估和比较列线图与终末期肝病模型(MELD)、Child-Pugh 和白蛋白-胆红素(ALBI)评分的区分度、校准度和临床实用性。
内镜治疗后 6 周内 39 例(32.8%)患者发生早期再出血。独立的早期再出血危险因素包括胃静脉曲张出血(GVH)、合并肝细胞癌(HCC)、国际标准化比值(INR)和肌酐。该列线图具有出色的校准和区分能力。列线图的曲线下面积为 0.758(95%CI 0.668-0.848),通过交叉验证和 bootstrap 验证验证为 0.71。DCA 和 ROC 曲线表明,该列线图优于 MELD、Child-Pugh 和 ALBI 评分。
与现有的预测评分相比,该列线图在预测内镜治疗 EGVH 后患者再出血方面具有更高的区分度、校准度和临床适用性。因此,它可能有助于临床医生早期实施积极的治疗和随访。